New Research: Develop a Resilient Hybrid Work Model for Your Commercial Biopharma Organization
CHAPEL HILL, N.C., Sep. 21, 2022/PRNewswire/ -- With the pandemic now reaching a waning stage in most parts of the world, 70% of Commercial leaders believe that workplace flexibility for commercial roles “is here to stay.”
Hybrid workforces are given little navigation from leadership as to what kinds of activities are best performed in-person vs. virtual. There are enough factors in play that it can make it difficult to use personal judgment when determining what is well-suited to different work models.
According to Best Practices, LLC’s client-based research, activities that are seen as a poor fit for virtual execution include:
“Developing the Best Hybrid Work Model for Your Commercial Biopharma Organization” is a 50-pagestudy that investigates the changing forms, features, conditions, and triggers for hybrid work models that are driving success within pharma sales, marketing and other commercial functions.
Key topics in the report include:
- Types of Commercial Work Models
- Activities and Staffing in Successful Hybrid Models
- Delivering Value in Commercial Sales
- Facility Accommodations
- Key Lessons Learned for a High-functioning Hybrid Business Model
- Benefits and Barriers of Hybrid Work Environment
Best Practices, LLC engaged 23 Commercial leaders from 20 pharma companies in this benchmarking research.
Review a complimentary summary of the study at https://www.best-in-class.com/rw142.htm.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.